|
TOP STORY |
Synthesis and Delivery of Short, Noncoding RNA by B Lymphocytes Scientists demonstrated that primary B lymphocytes can be genetically programmed with nonviral plasmid DNA for the biogenesis and delivery of antisense sequences (anti-microRNA) against microRNA-150. [Proc Natl Acad Sci USA] Abstract | Press Release |
PUBLICATIONS (Ranked by impact factor of the journal) |
Platelet Gene Therapy Corrects the Hemophilic Phenotype in Immunocompromised Hemophilia A Mice Transplanted with Genetically Manipulated Human Cord Blood Stem Cells Scientists evaluated the feasibility for lentivirus (LV)-mediated human platelet gene therapy of hemophilia A. Human platelet-FVIII (2bF8) expression was introduced by 2bF8LV-mediated transduction of human cord blood CD34+ cells followed by xeno-transplantation into immunocompromised NSG mice or NSG mice in a FVIIInull background. [Blood] Abstract MSC-Based VEGF Gene Therapy in Rat Myocardial Infarction Model using Facial Amphipathic Bile Acid-Conjugated Polyethyleneimine Tissue Engineered Bulking Agent with Adipose-Derived Stem Cells and Silk Fibroin Microspheres for the Treatment of Intrinsic Urethral Sphincter Deficiency Donor Mesenchymal Stromal Cells (MSCs) Undergo Variable Cardiac Reprogramming In Vivo and Predominantly Co-Express Cardiac and Stromal Determinants after Experimental Acute Myocardial Infarction Adipose-Derived Stem Cells Exhibit Antioxidative and Antiapoptotic Properties to Rescue Ischemic Acute Kidney Injury in Rats Nanoparticle Delivery of the Bone Morphogenetic Protein 4 Gene to Adipose-Derived Stem Cells Promotes Articular Cartilage Repair In Vitro and In Vivo MicroRNA-23a Is Involved in Tumor Necrosis Factor-α Induced Apoptosis in Mesenchymal Stem Cells and Myocardial Infarction Characterization of a Biodegradable Coralline Hydroxyapatite/Calcium Carbonate Composite and Its Clinical Implementation |
REVIEWS |
Mesenchymal Stromal Cells to Promote Kidney Transplantation Tolerance The authors review recent evidence on both the beneficial and deleterious effects of mesenchymal stromal cell (MSC) in experimental models of solid organ transplantation as well as first clinical experiences of MSC therapy in kidney transplant recipients. [Curr Opin Organ Transplant] Abstract Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research field. |
SCIENCE NEWS |
Tocagen’s Toca 511 Gene Therapy with Toca FC Was Well Tolerated and Showed Antitumor Activity in Patients with High Grade Glioma Tocagen Inc. announced that interim clinical data from two ongoing Phase I investigational studies showed that Toca 511 administration followed by courses of oral Toca FC was safe and well tolerated in 60 patients treated to date with recurrent high grade glioma. In addition, data were presented showing that in tumor samples taken from some patients following treatment, Toca 511 selectively infected tumor cells and expressed a cytosine deaminase transgene. [Press release from PR Newswire Association LLC discussing research presented at the Society for Neuro-Oncology (SNO) Annual Meeting, San Francisco] Press Release Celldex Therapeutics’ Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-Positive Recurrent Glioblastoma From our sponsor: Free Nature Reviews Immunology poster – Immune Response to HIV. Request a copy. |
POLICY |
23andMe Ordered to Halt Sales of DNA Tests The US Food and Drug Administration (FDA) has ordered personal-genomics company 23andMe to stop marketing its DNA-testing service. In a warning letter dated November 22, the FDA , says that 23andMe has not provided information showing that its service is safe and effective. [Nature News] Editorial UK Government’s Overspending Could Hit Science Budget |
BUSINESS |
Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics Editas Medicine, a genome editing company, announced it has secured a $43 million Series A financing led by Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund. [Editas Medicine] Press Release $500,000 Alliance for Cancer Gene Therapy Grant to Fund Breakthrough Brain Cancer Research University of Utah Doctor Performs Historic First Procedure Using New Technique of Retrograde Gene Therapy on a Human Heart NTCELL Clinical Trial: Recruitment of Further Patients Approved VBL Therapeutics Receives FDA Fast Track Designation for Lead Compound VB-111 ATL1102 for Stem Cell Mobilization: Application to Conduct Human Proof of Concept Clinical Trial Submitted Recognition for Tissue Engineering Success Tiffany Vo Wins Ruth L. Kirschstein National Research Service Award Blue Horizon International Creates Stem Cell Education Broadcast for Public TV |
NIH |
Center for Scientific Review; Notice of Closed Meetings (FR Doc No: 2013-28267) |
CBER |
Approval Letter – IPOL |
REGULATORY |
Food and Drug Administration (United States) |
EVENTS |
NEW Gordon Research Seminar: Craniofacial Morphogenesis & Tissue Regeneration March 29-April 4, 2014 Lucca, Italy Visit our events page to see a complete list of events in the cell, gene and immunotherapy community. |
SUBSCRIBER TOOLS: | |||
Profile Center | Connexon Publications | Article Submission | Contact Us |